Ginkgo Bioworks Holdings, Inc. (DNA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$188.7M
Cash & Equivalents
$46.7M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$569M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03158090 | The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research | OTHER | Recruiting | 1,965 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.